Management of Progressive Supranuclear Palsy – Evidence‑Based Recommendations
Diagnostic Confirmation and Phenotype Recognition
- Accurate clinical confirmation of PSP and identification of the specific phenotype (e.g., Richardson’s syndrome, PSP‑PGF, PSP‑CBS) is essential because phenotype determines prognosis and guides therapeutic priorities. 1, 2, 3, 4
- PSP‑Richardson’s syndrome is characterized by early postural instability, supranuclear gaze palsy, and variable cognitive/behavioral changes; it follows a rapid disease course with a median survival of 5–7 years. 1
- The underlying neuropathology is most often frontotemporal lobar degeneration with PSP‑type tau aggregates (FTLD‑PSP); FTLD‑corticobasal degeneration and, rarely, Lewy‑body disease may also be present. 1, 2, 3, 4
Pharmacological Management
Motor Symptoms
- A therapeutic trial of levodopa (up to 1000–1500 mg/day in divided doses) for 3 months is recommended; discontinue if no clear benefit is observed, as side‑effects can worsen functional status. 5
Cognitive and Behavioral Symptoms
- Cholinesterase inhibitors (rivastigmine or donepezil) may yield modest improvement in cognition; evidence is limited. 6
- When antipsychotic therapy is unavoidable for safety, use quetiapine at the lowest effective dose to minimize worsening of parkinsonism. 6
Sleep Disorders
- Melatonin (2.5–10 mg nightly) is suggested for insomnia management. 7
Pain, Spasticity, and Dystonia
- Gabapentin (300–1800 mg/day) or pregabalin (75–300 mg/day) can be employed for neuropathic pain. 8
- Botulinum toxin injections are effective for focal dystonia, particularly cervical dystonia. 8
Non‑Pharmacological Management
Ocular Motor Dysfunction
- Prism glasses to aid downgaze for reading and eating improve functional vision. 7
Dysphagia Management
- Refer patients to speech‑language pathology for instrumental swallowing assessment (FEES or videofluoroscopy) at the first sign of dysphagia. 5, 9
- Implement diet modifications (thickened liquids, pureed/soft foods) based on the swallowing study results. 5
- Discuss percutaneous endoscopic gastrostomy (PEG) when oral intake becomes unsafe or when weight loss exceeds 10 % or recurrent aspiration occurs. 5
Communication Strategies
- Early introduction of augmentative and alternative communication devices (speech‑generating devices or communication boards) while cognitive function still permits learning. 7
Nutritional Support
- Weigh the patient at every visit; investigate any weight loss > 5 % of baseline. 5, 9, 7
- Ensure protein intake of 0.8–1.0 g/kg body weight per day and supplement vitamin D as needed. 5
Multidisciplinary Care Coordination
- Schedule neurology follow‑up every 3–6 months to monitor disease progression and adjust medications. 7
- Integrate physical therapy (2–3 times weekly initially) and occupational therapy for gait training, balance, ADL adaptations, and home safety modifications.
- Include speech‑language pathology, dietitian, social work, and palliative‑care services as part of the core team.
Caregiver Support
Advance Care Planning
- Document a healthcare proxy and durable power of attorney for healthcare early while the patient retains decision‑making capacity. 7
Safety Considerations & Pitfalls
- Avoid chronic levodopa use without documented benefit; reassess response objectively and discontinue if ineffective. 5
- Do not employ standard antipsychotics without first exhausting non‑pharmacologic measures, as PSP patients are highly sensitive to these agents. 6
All recommendations are derived from peer‑reviewed sources indicated by the citation IDs. Strength of evidence varies; where not explicitly graded, the underlying literature reports limited or modest support.